{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:20:28Z","timestamp":1787872828238,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972698"],"award-info":[{"award-number":["81972698"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-047"],"award-info":[{"award-number":["2022-PUMCH-C-047"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-014"],"award-info":[{"award-number":["2021-I2M-1-014"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332023009"],"award-info":[{"award-number":["3332023009"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08471-w","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:23:19Z","timestamp":1781716999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiomics prediction and immunogenic validation of personalized neoantigens in cholangiocarcinoma patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Baoluhe","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueshuai","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang\u2019an","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunda","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"8471_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, Teh BT, Wongkham S, Gores GJ. Cholangiocarcinoma. Nat reviews Disease primers. 2021;7:65.","journal-title":"Nat reviews Disease primers"},{"key":"8471_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/hep.31200","volume":"72","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Kwong LN. Insights into the origin of intrahepatic cholangiocarcinoma from mouse models. Hepatology. 2020;72:305\u201314.","journal-title":"Hepatology"},{"key":"8471_CR3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/14728222.2021.2010046","volume":"25","author":"J Wang","year":"2021","unstructured":"Wang J, Loeuillard E, Gores GJ, Ilyas SI. Cholangiocarcinoma: what are the most valuable therapeutic targets\u2013cancer-associated fibroblasts, immune cells, or beyond T cells? Expert Opin Ther Targets. 2021;25:835\u201345.","journal-title":"Expert Opin Ther Targets"},{"key":"8471_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.21037\/hbsn-22-555","volume":"12","author":"WJ Choi","year":"2023","unstructured":"Choi WJ, Sapisochin G. Pushing the limits for the surgical treatment of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2023;12:99.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"8471_CR5","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","volume":"39","author":"S Affo","year":"2021","unstructured":"Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, Chin L, Filliol A, Wen W, Song X. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell. 2021;39:866\u201382. e811.","journal-title":"Cancer Cell"},{"key":"8471_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.21037\/hbsn-23-255","volume":"12","author":"I Amygdalos","year":"2023","unstructured":"Amygdalos I, Neumann UP, Lang SA. Targeted therapies in cholangiocarcinoma: light at the end of the tunnel? Hepatobiliary Surg Nutr. 2023;12:631.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"8471_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69\u201374.","journal-title":"Science"},{"key":"8471_CR8","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1158\/2159-8290.CD-16-0146","volume":"6","author":"R Mandal","year":"2016","unstructured":"Mandal R, Chan TA. Personalized oncology meets immunology: the path toward precision immunotherapy. Cancer Discov. 2016;6:703\u201313.","journal-title":"Cancer Discov"},{"key":"8471_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrc.2016.154","volume":"17","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Johnson BA III, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017;17:209\u201322.","journal-title":"Nat Rev Cancer"},{"key":"8471_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217\u201321.","journal-title":"Nature"},{"key":"8471_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 2020;183:347\u201362. e324.","journal-title":"Cell"},{"key":"8471_CR12","doi-asserted-by":"publisher","first-page":"e150535","DOI":"10.1172\/JCI150535","volume":"132","author":"NP Kristensen","year":"2022","unstructured":"Kristensen NP, Heeke C, Tvingsholm SA, Borch A, Draghi A, Crowther MD, Carri I, Munk KK, Holm JS, Bjerregaard A-M. Neoantigen-reactive CD8\u2009+\u2009T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma. J Clin Investig. 2022;132:e150535.","journal-title":"J Clin Investig"},{"key":"8471_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41698-022-00279-3","volume":"6","author":"Z Guo","year":"2022","unstructured":"Guo Z, Yuan Y, Chen C, Lin J, Ma Q, Liu G, Gao Y, Huang Y, Chen L, Chen L-Z. Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer. NPJ Precision Oncol. 2022;6:34.","journal-title":"NPJ Precision Oncol"},{"key":"8471_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","volume":"6","author":"Z Ding","year":"2021","unstructured":"Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, Wang P, Su X, Qin Y, Wang Y. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target therapy. 2021;6:26.","journal-title":"Signal Transduct Target therapy"},{"key":"8471_CR15","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"CD Palmer","year":"2022","unstructured":"Palmer CD, Rappaport AR, Davis MJ, Hart MG, Scallan CD, Hong S-J, Gitlin L, Kraemer LD, Kounlavouth S, Yang A. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2022;28:1619\u201329.","journal-title":"Nat Med"},{"key":"8471_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-021-01467-8","volume":"20","author":"Z Cai","year":"2021","unstructured":"Cai Z, Su X, Qiu L, Li Z, Li X, Dong X, Wei F, Zhou Y, Luo L, Chen G. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion. Mol Cancer. 2021;20:1\u201313.","journal-title":"Mol Cancer"},{"key":"8471_CR17","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/2326-6066.CIR-21-0931","volume":"10","author":"S Peng","year":"2022","unstructured":"Peng S, Chen S, Hu W, Mei J, Zeng X, Su T, Wang W, Chen Z, Xiao H, Zhou Q. Combination neoantigen-based dendritic cell vaccination and adoptive T-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma. Cancer Immunol Res. 2022;10:728\u201344.","journal-title":"Cancer Immunol Res"},{"key":"8471_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ymeth.2005.11.006","volume":"38","author":"JH Cox","year":"2006","unstructured":"Cox JH, Ferrari G, Janetzki S. Measurement of cytokine release at the single cell level using the ELISPOT assay. Methods. 2006;38:274\u201382.","journal-title":"Methods"},{"key":"8471_CR19","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.annonc.2021.04.012","volume":"32","author":"T Bekaii-Saab","year":"2021","unstructured":"Bekaii-Saab T, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol. 2021;32:1111\u201326.","journal-title":"Ann Oncol"},{"key":"8471_CR20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.21037\/hbsn.2019.08.05","volume":"8","author":"L Xue","year":"2019","unstructured":"Xue L, Guo C, Zhang K, Jiang H, Pang F, Dou Y, Liu X, Lin H, Dong X, Zhao S. Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice. Hepatobiliary Surg Nutr. 2019;8:615.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"8471_CR21","doi-asserted-by":"publisher","first-page":"e2100510","DOI":"10.1200\/PO.21.00510","volume":"6","author":"K Mody","year":"2022","unstructured":"Mody K, Jain P, El-Refai SM, Azad NS, Zabransky DJ, Baretti M, Shroff RT, Kelley RK, El-Khouiery AB, Hockenberry AJ. Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures. JCO Precision Oncol. 2022;6:e2100510.","journal-title":"JCO Precision Oncol"},{"key":"8471_CR22","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","volume":"28","author":"LA Donehower","year":"2019","unstructured":"Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, Li X, Babur O, Hsu T-K, Lichtarge O. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep. 2019;28:1370\u201384. e1375.","journal-title":"Cell Rep"},{"key":"8471_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar SR, Velcheti V, Neel BG, Wong K-K. The current state of the art and future trends in RAS-targeted cancer therapies. Nat reviews Clin Oncol. 2022;19:637\u201355.","journal-title":"Nat reviews Clin Oncol"},{"key":"8471_CR24","doi-asserted-by":"publisher","first-page":"e003214","DOI":"10.1136\/jitc-2021-003214","volume":"9","author":"X Chen","year":"2021","unstructured":"Chen X, Wang D, Liu J, Qiu J, Zhou J, Ying J, Shi Y, Wang Z, Lou H, Cui J. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes. J Immunother Cancer. 2021;9:e003214.","journal-title":"J Immunother Cancer"},{"key":"8471_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/intimm\/dxw019","volume":"28","author":"N Riaz","year":"2016","unstructured":"Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA. The role of neoantigens in response to immune checkpoint blockade. Int Immunol. 2016;28:411\u20139.","journal-title":"Int Immunol"},{"key":"8471_CR26","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976\u201386.","journal-title":"N Engl J Med"},{"key":"8471_CR27","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/eji.200737995","volume":"38","author":"MS Bijker","year":"2008","unstructured":"Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC\u2010focused antigen presentation. Eur J Immunol. 2008;38:1033\u201342.","journal-title":"Eur J Immunol"},{"key":"8471_CR28","doi-asserted-by":"publisher","first-page":"e164258","DOI":"10.1172\/JCI164258","volume":"133","author":"JS Dolina","year":"2023","unstructured":"Dolina JS, Lee J, Brightman SE, McArdle S, Hall SM, Thota RR, Zavala KS, Lanka M, Premlal ALR, Greenbaum JA. Linked CD4+\/CD8\u2009+\u2009T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression. J Clin Investig. 2023;133:e164258.","journal-title":"J Clin Investig"},{"key":"8471_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40164-022-00353-3","volume":"11","author":"W Zhou","year":"2022","unstructured":"Zhou W, Yu J, Li Y, Wang K. Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia. Experimental Hematol Oncol. 2022;11:100.","journal-title":"Experimental Hematol Oncol"},{"key":"8471_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40364-023-00534-0","volume":"11","author":"Z Pang","year":"2023","unstructured":"Pang Z, Lu M-m, Zhang Y, Gao Y, Bai J-j, Gu J-y, Xie L. Wu W-z: Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges. Biomark Res. 2023;11:104.","journal-title":"Biomark Res"},{"key":"8471_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1034\/j.1600-065X.2002.18803.x","volume":"188","author":"MJ Scanlan","year":"2002","unstructured":"Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer\/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002;188:22\u201332.","journal-title":"Immunol Rev"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08471-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08471-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08471-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:06:53Z","timestamp":1787872013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08471-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8471"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08471-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the principles of the Declaration of Helsinki. The study was approved by the Ethical Review Committee of Peking Union Medical College Hospital (I-23PJ1691). Informed consent had been obtained from all individuals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1105"}}